An international chemical and healthcare corporation retained CRA to conduct appraisal work related to the acquisition of a company in the diagnostics industry. The acquired entity was involved in developing, manufacturing, and marketing products, including testing kits, consumables, and systems (hardware and software) for the nucleic acid diagnostics market. CRA’s primary assignment was to determine the fair value of the company’s intangible assets in connection with the allocation of purchase price among the acquired assets. Additionally, CRA was asked to determine the fair value of the acquired company’s international subsidiaries.
IP Literature Watch: March 2025
We are pleased to present the latest edition of CRA’s IP Literature Watch. This issue contains pieces on antitrust & IP, licensing, litigation, innovation, law...